Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia)

Drug Design, Development and Therapy
Min Lin, Baoan Chen

Abstract

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy, characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. The new drugs used for treating AML are facing a big challenge, and the candidates include cytotoxic drugs, targeted small-molecule inhibitors, and monoclonal antibodies. In recent years, active research has focused on several new agents for including them in the large antileukemic drug family. This review aims to introduce some of these new drugs and highlights new advances made in the old drugs, mainly in the last 5 years.

Citations

Dec 20, 2019·Dose-response : a Publication of International Hormesis Society·Xiao HuangZhijun Yang

❮ Previous
Next ❯

Methods Mentioned

BETA
Histone acetylation
xenograft

Clinical Trials Mentioned

NCT02326584

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
T M KadiaH Kantarjian
Clinical Advances in Hematology & Oncology : H&O
Matthew R Skelton, Bert O'Neil
© 2022 Meta ULC. All rights reserved